SCHEMBL7267902

SCHEMBL7267902

Cc1ccc(CC(=O)O)c(C=Cc2ccccc2Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.44
FGFR3 P22607 1/20 0.44
RAB9A P51151 7/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
MAPT P10636 5/20 0.41
NPC1 O15118 5/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
POLB P06746 2/20 0.39
APAF1 O14727 1/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
UBE2N P61088 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGS2 P35354 2/20 0.39
CXCL8 P10145 3/20 0.39
MAOB P27338 1/20 0.38
LMNA P02545 3/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711228 0.84 FGFR1 (0.41) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL4711231 0.84 FGFR1 (0.41) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL7268783 0.83 MAPT (0.48) RAB9ASMN1; SMN2MAPTNPC1KMT2A
SCHEMBL4713060 0.80 RAB9A (0.46) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL4713064 0.80 RAB9A (0.46) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL4710664 0.79 PTGDR2 (0.45) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL4713003 0.79 PTGDR2 (0.45) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL4710062 0.79 FGFR1 (0.40) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL4710063 0.79 FGFR1 (0.40) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL7268766 0.79 PTGDR2 (0.45) RAB9ASMN1; SMN2MAPTNPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed